Use of antiepileptic drugs in a community-dwelling Dutch population by Lammers, M.W et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/23302
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Use of antiepileptic drugs in a 
community-dwelling Dutch population
M.W. Lammers, MD, PhD; Y.A. Hekster, PhD; A. Keyser, MD, PhD; H. Meinardi, MD, PhD;
W.O. Renier, MD, PhD; and R.M.C. Herings, PhD
Article abstract—We compared the treatment policy for patients with epilepsy in six Dutch cities, comprising 302,149 
inhabitants, with the treatment policies of a secondary referral center (a university hospital) and tertiary referral centers 
(outpatient departments of epilepsy centers). By comparing the prevalence of individuals receiving antiepileptic drugs in 
the six cities with the epidemiologic data for epilepsy in Rochester, Minnesota, we concluded that prescription data offer a 
suitable means by which to estimate the prevalence of epilepsy in a community, To compare prescriptions in cases of 
poly therapy, we normalized data by using defined daily doses published by the WHO Collaborating Center for Drugs 
Statistics Methodology and the Nordic Council on Medicines and concluded that the defined daily doses of antiepileptic 
drugs should be further elaborated. There is a need to obtain complete dose-response curves of equivalent antiepileptic 
drugs in humans. The trend of drug use found in the six cities, the university hospital, and the epilepsy centers is, 
however, in accord with the expectations regarding primary, secondary, and tertiary referral centers,
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Wijsman et a l1*2 compared the treatment offered by AEDs and to the role of monotherapy versus poly­
secondary- and tertiary-referral epilepsy centers and therapy, 
found substantial differences in drug utilization that 
disappeared when they matched patients for dura­
tion of epilepsy and seizure type, despite the fact 
that scores on a composite index of impairment in­
corporating information about seizure frequency, sei­
zure severity, and drug toxicity were higher at the 
tertiary level. To determine how the general popula­
tion of epileptics differs from those seen at secondary 
and tertiary referral centers, we examined the pat­
tern of antiepileptic drug (AED) utilization in the 
community. A drug database (PHARMO) from all 
pharmacies in a group of cities in The Netherlands 
provided the necessary information. Although AEDs 
can also be used for other indications, when they are, 
it is usually only for brief periods. Therefore, we 
included only the data of those who used AEDs con­
secutively for at least 6 months. As AEDs are avail­
able only on prescription, and as the collaborating 
pharmacies covered a population of known size, our 
data also yield an estimate of epilepsy prevalence.
There are several studies on the prevalence of epi­
lepsy in The Netherlands,3"6 but those focusing on 
the use of AEDs included only a small population of 
patients, most of them hospitalized.7,8 We compared 
the data from the PHARMO drug database with pre­
viously published data and with recently collected 
data from a secondary and a tertiary referral 
center.1-2
We also analyzed the data with respect to new
Methods. For the study on the use of AEDs, we obtained 
data from the PHARMO drug database. The structure of 
the PHARMO drug database has been described by Her­
ings.9 The data extracted were compared with data previ­
ously reported and also with more recently collected data 
using the same methodology.1 The cases studied were from 
the neurologic department of the University of Nijmegen 
(university hospital [UH]; N = 120) and from both the 
Instituut voor Epilepsiebestrijding “Meer en Bosch-De 
Cruquiushoeve” and the Dr Hans Berger Kliniek (epilepsy 
centers [EC]; N = 559). The studies were approved by the 
ethics committees of the participating institutions, and all 
patients involved gave informed consent.
The PHARMO drug database contains histories ob­
tained from 27 pharmacies covering all prescription drugs 
dispensed in six middle-sized Dutch cities with a total of 
approximately 300,000 inhabitants. Information on drug 
prescription by means of the PHARMO drug database has 
been collected for some cities since 1986, and for all six 
cities since 1989. The PHARMO drug database is re­
stricted to the community-dwelling part of the population 
in these six cities, i.e., data from nursing homes or institu­
tions for the mentally retarded are excluded.
For our study, we used data collected from 1989 on­
wards. These included the patient’s age and gender, drug 
prescribed, number of units dispensed, units per day used, 
and anticipated duration of use. From this data we defined 
patients as being exposed to one (monotherapy) or more 
(polytherapy) AEDs.
Next, normalized doses were obtained by dividing the
From the Institute of Neurology (Drs. Lammers, Keyser, Meinardi, and Renier), University Hospital Nijmegen, The Netherlands; Department of Clinical 
Pharmacy (Dr. Hekster), University Hospital Nijmegen, The Netherlands; and Department of Pharmacoepidemiology and Pharmacotherapy (Dr. Herings), 
Utrecht University, The Netherlands,
Supported by Commissie Landelijk Epilepsie Onderzoek (CLEO-NEF) grant no. A-81.
Received February 27, 1995. Accepted in final form May 17, 1995.
Address correspondence and reprint requests to Dr. H. Meinardi, c/o P.O. Box 21, 2100 AA Heemstede, The Netherlands.
62 Copyright © 1996 by the American Academy of Neurology
"Rocheste^ M in n ^ o ta  ^  ^  population in 1992 by age and gender, compared with epilepsy prevalence in
PH men
PH total n = 2,696 RO total n -  383
Age
PH women — ---------— -- ------------ _ --------— ~ —  —  — — ■ —
n = 1,257 (%) n = 1,439 (%) n (%) n (%)
0 -4 0.21 0.38 55 0.27 6 0,14
5-9 0.41 0.34 71 0.34 16 0.39
10-14 0.58 0.41 102 0.49 26 0.63
15-24 0.65 0.64 301 0.64 71 0.62
25-34 0.81 0.90 416 0.83 68 0.63
35-44 0.82 1.02 446 0.92 61 0.92
45-54 1.00 1.14 370 1.07 38 0.76
55-64 1.29 1.20 320 1.25 33 0.77
65-74 1.42 1.79 337 1.62 22 0.68
74+ 2.45 1.98 278 2.05 43 1.48
Total 0.83 0.94 2,696 0.89 383 0.68
n = num ber of patients using AEDs; % = percentage of patients using AEDs of the total population of the six Dutch cities or of all peo­
ple with epilepsy in Rochester; PH = the PHARMO population from the six Dutch cities (=302,149); RO = the Rochester population 
(=56,447; H auser et ai, 1991). Based on diagnosis of epilepsy.
prescribed daily dose (PDD) by the defined daily dose 
(DDD). For example, 50 mg twice a day (PDD = 100 mg) 
phénobarbital, which has a DDD of 100 mg, yields a PDD/ 
DDD ratio of 100 mg/100 mg, or 1,00. The normalized 
doses express the strength of the medication and, in cases 
of polytherapy, these units can be added to obtain the total 
strength of the combination (eg, if a patient is prescribed 
daily 600 mg carbamazepine [DDD = 1,000 mg] and 900 
mg valproate [DDD = 1,500 mg], the total PDD/DDD is 
1.2).
If the total daily dose was 0 or if the PDD/DDD ratio 
was >6, these entries were considered incorrect and de­
leted. This was the case for 1.8% of all records in 1989, 
1.5% in 1990, 0.6% in 1991, and 1.5% in 1992. The DDD 
was taken from the publications of the WHO Drug Utiliza­
tion Research Group, the WHO Collaborating Center for 
Drugs Statistics Methodology, and the Nordic Council on 
Medicines.10 The DDD is based on the assumed average 
dose per day expressed as the amount of the active sub­
stance of the drug used in its main indication in adults. A 
written dose document is prepared on the basis of interna­
tional textbooks, journals, and documentation approved by 
drug-control authorities. The dose documentations are 
available on request from the WHO in Oslo,
AEDs included in our study were carbamazepine (CBZ), 
clonazepam (CZP), ethosuximide (ESM), phénobarbital 
(PB), phenytoin (PHT), methsuximide (MSM), methylphe- 
nobarbital (MPB), oxcarbazepine (OCB), primidone (PRM), 
valproate (VPA), and vigabatrin (VGB). Diazepam (DZP), 
oxazepam (OZP), nitrazepam (NZP), clobazam (CLB), flu- 
narizine (FNR), and acetazolamide (AZM) were excluded 
even though these drugs were present in the prescriptions 
of the UH and EC populations, as confusion with chronic 
administration for other disorders was apt to occur.
To evaluate the use of a newly introduced drug, the 
dispensing histories of the patients using VGB in 1992 
were assessed separately from 1989 until 1992.
Patients who used one or more of the AEDs during a 
period longer than 180 days were defined as patients hav­
ing epilepsy. This period was considered sufficient for the 
elimination of those patients who used these drugs inci­
dentally for indications other than epilepsy. However, in 
addition to the long-term use of AEDs in the treatment of 
epilepsy, there is a tendency to use AEDs also for longer 
periods in certain psychiatric disorders and trigeminal 
neuralgia. We shall come back to this point in the Discus­
sion.
The percentage of patients in the population of 1992 
using one or more AEDs according to the aforementioned 
criterion was considered to be the period prevalence of 
epilepsy. The data were compared with the 1980 data from 
Rochester, Minnesota, reported by Hauser et al.n
Statistical analysis. In the analysis of AED distribution 
or number of AEDs used from 1989 to 1992 and for the 
analysis of prevalence across the age groups, the x2 test 
was applied. For the analysis of prevalence by gender, the 
combination of the x2 tests over the age categories was 
applied. Statistical significance was defined at p  <  0.05.
Results. Antiepileptic drugs used. According to the 
Dutch Central Bureau for Statistics, the total population of 
the six cities on January 1, 1992, was 302,149; there were 
149,647 men (49.5%) and 152,502 women (50.5%).12 In this 
population, 2,696 people (0.89%) used one or more AEDs. 
The use of AEDs increased with age by a statistically sig­
nificant degree for both men and women. The highest prev­
alence was observed among men 75 years of age and older. 
No statistically significant difference in prevalence was ob­
served between men and women in any age group (table 1).
Approximately 80% of the patients were treated with 
monotherapy. Two AEDs were used by 16%, three by 4%, 
four by 0.4%, and five by 0.04%.
The use of individual AEDs by the PHARMO population 
in 1992 is detailed in table 2; information about the use of 
these drugs in the UH and EC populations is presented for
comparison.
In the PHARMO population, a statistically significant 
(p < 0.05) decrease was seen during 1989-1992 in the
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Table 2 Use o f  antiepileptic drugs (AEDs) in the PHARMO population as compared with published data on prescriptions from. UH and
EC populations
PH 1992 
n = 2,467 
PDD/DDD
UH
n = 120
PDD/DDD
EC
n = 559 
PDD/DDD P II 1992 
n = 2,467 
(%)
UH
n -  120 (%)
EC
n = 559 (%)M A M A M A
CBZ 0.60 0.55 0.60 0.66 0.80 0.93 49.4 56.7 70.1
VPA 0.60 0.65 0.63 0.75 0.80 0.90 24.6 27.5 42.4
PHT 0.61 0.69 1.00 0.90 1.10 1.15 24.3 26.7 27.5
PB 0.90 0.96 1.15 1.25 0,50 0.71 12.1 18.3 9.8
CZP 0.19 0.26 0.50 0.50 0.13 0.17 9.3 1.7 2.3
VGB 0.50 0.70 0,00 0.00 0.75 0.72 3.3 0.0 12.5
CLB n.r. n.r. 0.00 0.00 1.00 0.87 n.r. 0.00 15,4
PRM n.r. n.r. n.r. n.r. n.r. n.r. 1.6 3.3 3.0
ESM n.r. n.r. n.r. n.r. n.r. n.r. 1.2 0.8 4.5
MPB n.r. n.r. n.r. n.r. n.r. n.r. 0.7 0.0 0.0
MSM n.r. n.r. n.r. n.r. n.r. n.r. 0.2 0.0 0.0
OCB n.r. n.r. n.r. n.r. n.r. n.r. 0,2 0.0 2.9
DZP n.r. n.r. n.r. n.r. n.r. n.r. n.r. 0.8 0.5
OZP n.r. n.r. n.r. n.r. n.r. n.r. n.r. 0.8 0.0
FNR n.r. n.r. n.r. n.r. n.r. n.r. n.r. 0.0 0.7
AZM n.r. n.r. n.r. n.r. n.r. n.r. n.r. 0.0 1.3
NZP n.r. n.r. n.r. n.r. n.r. n.r. n.r. 0.0 0.4
Cumul. PDD/DDD 0.60 0.82 1,00 1.55 1.60 1.74 --- --------- ---------
To taF --------- — --------- --------- 126.9 136.6 193.3
* Some patien ts used more than  one AED.
For abbreviations of drug names see text. PH = population in PHARMO database; UH = university hospital; EC = epilepsy centers 
(Wijsman et al, 19933); PDD/DDD = ratio of the prescribed daily dose to the defined daily dose; n = num ber of patien ts older th an  15 
years of age; M = median value; A = average (mean) value; n.r. = not registered (see text); Cumul, PDD/DDD = m edian and average 
of tlie sums of the ratios of each AED and its proper defined daily dose prescribed per patient; % = percentage of patien ts using a p a r­
ticular AED,
percentage of patients using MPB (2.1% to 0.7%) and PB 
(14.8% to 12.1%). There was also a statistically significant 
(p < 0.05) increase in the percentage of patients using CZP 
(7.1% to 9.3%).
New drugs on the market. VGB was registered in 1990 
and OCB in 1991; however, until 1995 OCB was only 
partly reimbursed by insurance companies. The percent­
age of patients using OCB increased from 0,1% in 1991 to 
0.2% in 1992. Those patients who used VGB in 1992 were 
studied separately as of 1989 as the “VGB group.” The 
percentage of patients in the VGB group receiving mono­
therapy declined from 46% in 1989 to 11% in 1992. Over a 
period of three years, the percentage of patients using 
VGB increased from 0.2% to 3.3%. In 1992, 16 of the 90 
patients (17,7%) stopped using VGB. No patients stopped 
using VGB during 1990 or 1991. In 1990, when VGB was 
registered in The Netherlands, no patient in the VGB 
group used this AED as monotherapy. In 1992, 11% of 
these patients used VGB as monotherapy, compared with 
an 80% use of monotherapy overall.
When another AED was prescribed with VGB, the most 
frequently used was CBZ, followed by VP A. In triple ther­
apy, VGB was most frequently prescribed in combination 
with CBZ and VPA.
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Most frequently prescribed drugs. In all years CBZ was 
the most frequently prescribed AED used as monotherapy, 
followed by VPA and PHT.
When two AEDs were used, the combination of CBZ 
with VPA occurred most often, followed by the combination 
of CBZ with PHT.
The percentage of patients on monotherapy differed 
considerably between the three populations studied. Mono­
therapy was used by only 35% of the patients from, the EC 
and by 65.2% of the patients from the UH, while almost 
80% of the PHARMO population was treated with mono­
therapy {p <  0.05). The average number of drugs pre­
scribed per patient was 1.3 in the PHARMO group, 1.4 in 
the UH population, and 1.9 in the EC population (table 2). 
As in the PHARMO population, CBZ was the drug most 
often prescribed as monotherapy in both the EC and the 
UH populations. Also, when two AEDs were prescribed the 
combination most frequently used was CBZ with VPA, fol­
lowed by the combination of CBZ with PHT.
Dosing. In table 2 the median and average PDD/DDD 
ratios are presented for the drugs used in over 5% of the 
respective cohorts. Instances in which the PDD/DDD ratio 
was 0.00 or >6.00 were considered inaccuracies and were 
excluded from the assessment. Also, patients under 15
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Figure. Distribution of the total dose per day of antiepileptic drugs prescribed to patients registered in the PHARMO da­
tabase (N = 2,467) (A) and to patients attending outpatient departments of epilepsy centers (N -  559) (B), expressed as 
prescribed daily dose I defined daily dose ratios (pdd/ddd).
years were excluded in the PDD/DDD analysis in order to 
allow comparison with the UH and EC data.
In the PHARMO population, the median and average 
PDD/DDD ratios were all lower than 1.00. This was also 
the case in the UH and EC populations, except for PHT. 
PB was close to unity in the PHARMO population, higher 
than unity in the UH, but much less than unity in the EC, 
where it was also used much less frequently, CLB was 
used in only 15.4% of the EC patients, with a median 
PDD/DDD ratio of 1.0.
The frequency of use of CZP in the PHARMO popula­
tion is surprising; however, the median and average PDD/ 
DDD ratios for CZP were relatively low.
The highest doses per drug were used by patients under 
the care of the EC, while those who attended the UH hold 
an intermediate position. This is also reflected in the com­
parison of the total dose, whether it be of patients using 
monotherapy or poly therapy (cumulated PDD/DDD ratios).
The distribution of the cumulated PDD/DDD ratios per 
patient is illustrated for the PHARMO population in 1992 
and the EC population in the figure.
Discussion. The results of this study show that 
0.89% of a Dutch community of 302,149 people used 
AEDs longer than 180 days and therefore likely had 
epilepsy. Although reasons of privacy prevented us 
from verifying that assumption, comparison of the 
assumed number of epileptics found in this study
with the epilepsy prevalence in Rochester, Minneso­
ta,11 shows them to be remarkably close, especially 
for the age group 5 to 4-4 years old (table 1) 
(PHARMO prevalence = 0.72%; Rochester preva­
lence = 0.65%; difference is not significant [p > 0.1]). 
The difference between the average prevalence esti­
mated for all age groups in the PHARMO population 
(0.89%) and that in Rochester (0.68%), however, is 
highly significant (p < 0.001). The deviation, for 
which the age groups >44 years old are mainly re­
sponsible, may be explained by our study’s using as 
the only criterion for the diagnosis of epilepsy the 
use of AEDs for more than 180 days. It may be 
argued that nowadays some patients with trigeminal 
neuralgia or mania are also treated for prolonged 
periods with at least one of the AEDs, ie, CBZ. In a 
recent population-based door-to-door study of all 
elderly people living in Ommoord, a suburb of Rot­
terdam, The Netherlands, 5,559 persons aged 55 to 
95 were interviewed.13 Ninety-seven reported epi­
lepsy, and 24 used AEDs without reporting epilepsy. 
Of these 24, four had epilepsy but had not been told 
or had not understood that such was the case; seven 
used CBZ for trigeminal or hypoglossal neuralgia, 
two for polyneuropathy, and one for manic-depres­
sive psychosis; five were long-term barbiturate users 
with nervous disorders; three were prescribed CZP 
for restless legs; one was prescribed VPA after an
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attack of herpes encephalitis (without clinical or 
EEG evidence of epilepsy); and in one person verifi­
cation was impossible. Thus, a risk of overreporting 
of 20% could be inherent in our method. The type of 
disorders AEDs are used for apart from epilepsy in­
creases the likelihood of contamination, chiefly from 
middle age onwards. Even after correction by 20%, 
the differences in the prevalence of epilepsy between 
this study and the Rochester study remain signifi­
cant (p <  0.01) for the age groups from 45 to 74 years 
old; the difference for the age group 74+ is not sig­
nificant due to the steep increase in the Rochester 
data. The higher prevalence of epilepsy in these 
Dutch towns cannot be explained by a selection bias, 
as the patients in the PHARMO population were all 
outpatients who collected their own medication from 
one of the pharmacies in the database. The six towns 
covered by the study do not have institutions for 
mentally retarded or epilepsy centers, both of which 
would have attracted patients from outside the re­
gion, thus influencing the prevalence. As the Roches­
ter data covered the period 1940-1980 and the 
PHARMO drug database covered 1989-1992, the dif­
ference may depend on differences in diagnosis or in 
the composition of the population older than forty- 
five.
The percentage of patients on monotherapy was 
almost 80% in the PHARMO population, in agree­
ment with Reynolds and Shorvon,14 who showed that 
72% of epileptics can be well controlled with mono­
therapy. The percentage of patients on monotherapy 
in studies performed over the years shows a definite 
tendency toward monotherapy for the treatment of 
epilepsy.15“19
There were few changes in the AEDs prescribed 
over the years, with only MPB and PB showing a 
distinct decrease. MPB was most likely used by older 
patients, and the decrease in use could be explained 
by increased mortality among the elderly patients 
and by MPB’s not being prescribed for newly diag­
nosed patients.
The number of users of CZP is surprising because 
patients may develop a tolerance for this drug, mak­
ing it less advantageous for chronic treatment.
For most AEDs the median PDD/DDD ratio was 
well under 1.00, the reason possibly being that the 
DDD, as recommended by the WHO, is too high. The 
WHO Collaborating Center for Drugs Statistics in 
Oslo presents the DDD of OCB as being equal to the 
DDD of CBZ, while clinical trials show that the DDD 
of OCB should be IV2 times the DDD of CBZ.20'22 
Further studies normalizing the dosages using PDD/ 
DDD ratios may require more accurate assessment 
of equipotence of the AEDs at several dose levels.
The percentage of prescriptions of VGB increased 
rapidly after its introduction in 1990, and the per­
centage of patients using VGB as monotherapy also 
increased considerably during the 3-year period, al­
though VGB was primarily registered as add-on 
therapy for partial seizures. That the overall per­
centage of patients on monotherapy decreased and
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the average number of AEDs per patient increased 
in the VGB group is explained by VGB’s mostly be­
ing used for patients with intractable seizures and 
not those with well-controlled epilepsy. The pattern 
of drug use in the PHARMO group resembled that of 
a secondary referral center since patients with epi­
lepsy are usually referred to a secondary referral 
center for confirmation of diagnosis and regulation of 
therapy.
In the EC, a greater variety of AEDs were used 
and more patients used a larger amount of antiepi­
leptic medication, as expressed in the sum of PDD/ 
DDD ratios per patient. That about 27% of the pa­
tients at the EC are treated with less than 1.00 PDD/ 
DDD probably reflects tha t not only therapy- 
resistant patients are referred to tertiary  care 
centers but also patients with psychosocial problems.
We conclude that prescription data of AEDs used 
for over 180 days can be used as an indicator for the 
prevalence of epilepsy, although for the middle-aged 
and elderly a correction factor has to be applied. The 
concept of normalizing prescriptions on the basis of 
DDDs facilitates comparison of treatment policies 
and treatm ent outcomes. However, the DDDs of 
AEDs should be refined; in particular, there is a 
need to obtain complete dose-response curves of 
equivalent AEDs.
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